FCGR3A and non-Hodgkin lymphoma: In a clinical trial involving patients with R/R high-grade NHL, researchers demonstrated that the administration of a low dose of rlL2 early after autologous HSCT for a duration of one year is well-tolerated and leads to the in vivo expansion of CD16+/CD56+ NK cells.